These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176 [TBL] [Abstract][Full Text] [Related]
4. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358 [TBL] [Abstract][Full Text] [Related]
5. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901 [TBL] [Abstract][Full Text] [Related]
7. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Bokstein F; Shpigel S; Blumenthal DT Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors. Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900 [TBL] [Abstract][Full Text] [Related]
9. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802 [TBL] [Abstract][Full Text] [Related]
12. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404 [TBL] [Abstract][Full Text] [Related]
13. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892 [TBL] [Abstract][Full Text] [Related]
14. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927 [TBL] [Abstract][Full Text] [Related]
16. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. Kang TY; Jin T; Elinzano H; Peereboom D J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Taillibert S; Vincent LA; Granger B; Marie Y; Carpentier C; Guillevin R; Bellanger A; Mokhtari K; Rousseau A; Psimaras D; Dehais C; Sierra del Rio M; Meng Y; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY Neurology; 2009 May; 72(18):1601-6. PubMed ID: 19414728 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab is active as a single agent against recurrent malignant gliomas. Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964 [TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]